Lakewood-Amedex Biotherapeutics Inc. has successfully completed the redemption of all outstanding shares of its Series C Convertible Preferred Stock. This strategic move is significant for the company as it simplifies its capital structure and enhances financial flexibility.
The redemption, which occurred on November 4, 2026, involved the repurchase of 127,097 shares at a total cost of $1,270,970. The funds for this transaction were sourced from the company’s available cash. Following this redemption, Lakewood-Amedex will no longer have any outstanding preferred stock, which eliminates potential dilution from share conversions and removes financing restrictions associated with the Series C Preferred Stock.
Background
Lakewood-Amedex Biotherapeutics Inc. operates within the pharmaceutical preparations sector, specifically focusing on developing a novel class of fast-acting, broad-spectrum antimicrobials. The company is publicly traded on the Nasdaq under the ticker symbol LABT. As an emerging growth company, Lakewood-Amedex is committed to advancing its clinical programs aimed at addressing infectious diseases.
What the Filing Says
According to the recent SEC filing, the company entered into a Share Redemption Agreement with Shakawe Capital LLC on November 2, 2026. The agreement stipulated that the company would redeem all outstanding shares of Series C Preferred Stock for cash. The filing noted, "Following the redemption, the shares were returned to the treasury and no shares of Series C Preferred Stock remain outstanding." This completion of the redemption was confirmed in a press release issued on November 5, 2026.
Impact
This redemption may positively impact various stakeholders, including shareholders and potential investors, by providing a clearer capital structure. The elimination of preferred shares reduces the risk of dilution, which can enhance shareholder value. Furthermore, this move may attract future investments as the company demonstrates financial stability and flexibility in its operations.
What's Next
The filing does not say what happens next. However, Lakewood-Amedex plans to file the full text of the Redemption Agreement as an exhibit to its Annual Report on Form 10-K for the fiscal year ending December 31, 2026. This will provide further insights into the agreement and its implications for the company’s future.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





